Výsledky vyhledávání - "Dan Beverly Fu"

Akademický článek

Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma

Autor: Steven Du, Dan Beverly Fu, Daniela A Bota, Xiao-Tang Kong

Publikováno v: CNS Oncology, Vol 13, Iss 1 (2024)

Background: Treatment for refractory or relapsed primary CNS lymphoma (r/r PCNSL) is challenging. Salvage whole-brain radiation therapy (WBRT) is an option but has a short duration of disease control, so additional treatment modalities are warranted.

Externí odkaz: https://doaj.org/article/6fcd878256e3438f9e1ab60ab76be183

Zobrazit plný text záznamu

Adherence to Prophylactic Anticonvulsant Guidelines for Newly Diagnosed Brain Tumor Patients: A Quality Improvement Study

Autor: Dan Beverly Fu, DNP, MBA, NP-C, Xiao-Tang Kong, MD, PhD, Tener Goodwin Veenema, PhD, MPH, MS, Daniela A. Bota, MD, PhD, Binu Koirala, PhD, MGS, RN

Publikováno v: Journal of the Advanced Practitioner in Oncology. 13:775-789

Background and Purpose: Clinical guidelines suggest that prophylactic antiepileptic drugs (AEDs) should be given to newly diagnosed seizure-naive brain tumor patients for up to 1 week after craniotomy. Yet, data suggest that prophylactic AEDs are use

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85785c95111188a8ae8ceedea312883a
https://doi.org/10.6004/jadpro.2022.13.8.4

Zobrazit plný text záznamu

PATH-06. QUANTITATIVE ANALYSIS OF MGMT PROMOTER METHYLATION AND ITS PROGNOSTIC VALUE IN GLIOBLASTOMA MULTIFORME (GBM) PATIENTS TREATED WITH ALKYLATING CHEMOTHERAPY- PRELIMINARY REPORT

Autor: Xiao-Tang Kong, Lisa A. Flanagan, Stephania Hernandez, Samarjeet Bajwa, Daniela A. Bota, Dan Beverly Fu

Publikováno v: Neuro-oncology, vol 20, iss Suppl 6
Neuro-Oncology, vol 20, iss suppl_6

OBJECTIVE To correlate the percentage of MGMT methylation with progression-free survival (PFS) and overall survival (OS) in GBM patients receiving alkylating chemotherapy. BACKGROUND MGMT promoter methylation is a known favorable factor for patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8469ebbe889e98714a77dc983995de11
https://escholarship.org/uc/item/5n79d7jn

Zobrazit plný text záznamu

ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN

Autor: Dan Beverly Fu, Frank L. Meyskens, Daniela A. Bota, Xiao-Tang Kong, Jose Carrillo, Albert Lai

Publikováno v: Neuro-Oncology, vol 20, iss suppl_6
Neuro-oncology, vol 20, iss Suppl 6

OBJECTIVE: To investigate the toxicity, tolerability and efficacy of the combination of ixazomib and standard chemoradiation therapy for newly diagnosed MGMT methylated GBM patients. BACKGROUND GBM is the most aggressive primary malignant brain tumor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::657e5ea19e1c2ec85e25c5b17600a99b
https://europepmc.org/articles/PMC6216158/

Zobrazit plný text záznamu

ATIM-28. Phase 2 study of ERC1671 plus bevacizumab vs bevacizumab plus placebo in recurrent GBM interim results and correlations with CD4+ T lymphocyte counts

Autor: Dan Beverly Fu, Apostolos Stathopoulos, Raphael Zidovetzki, Jose Carrillo, Chrystel Pretto, Ankie Strik, Alex H Schönthal, Virgil E.J.C. Schijns, Daniela A. Bota, Xiao-Tang Kong, Jinah Chung, Thomas C. Chen, Florence M. Hofman, Frank P.K. Hsu, Manisha Dandekar

Publikováno v: Neuro-Oncology, vol 20, iss suppl_6
Neuro-Oncology 20 (2018) suppl_6
Neuro-Oncology, 20(suppl_6), vi7-vi7
Neuro-oncology, vol 20, iss Suppl 6

BACKGROUND ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors. Previously published compassionate use data

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26d2c3ca6a62c8f4602f865d5f5c9f3b
https://doi.org/10.1093/neuonc/noy148.023

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání